# Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

> **NCT01049984** · PHASE4 · COMPLETED · sponsor: **Teva Neuroscience, Inc.** · enrollment: 328 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Rasagiline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01049984
- **Lead sponsor:** Teva Neuroscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2016-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01049984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01049984, "Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01049984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*